BioVentures Investors

Georgiamune is an immunotherapy company that develops oncology-focused treatments. It advances next-generation immunotherapies and homeostatic therapies aimed at cancer and autoimmune diseases. The company's approach targets immune signaling pathways to reprogram the immune system and restore immune homeostasis, helping patients fight cancer and autoimmune conditions.

BRAINBox Solutions develops and manufactures diagnostic tests for traumatic brain injury, focusing on mild TBI. The company offers a multi-modality platform that combines blood biomarker panels with neurocognitive testing and point-of-care instruments to provide objective assessments of injury and recovery potential. Its quantitative test integrates injury-related blood biomarkers with computerized neurological assessments and delivers an AI-driven score to aid clinicians in predicting recovery and identifying ongoing symptoms. Founded in 2002 and based in Richmond, Virginia, BRAINBox Solutions serves healthcare providers with tools designed to improve diagnostic accuracy and prognosis for patients with mild TBI.

SonoMotion Inc. develops non-invasive medical devices for kidney stone disease, including Break Wave for fragmenting large stones and Stone Clear to remove fragments within about 15 minutes in office settings without general anesthesia or X-ray radiation. The company, founded in 2012 and based in San Mateo, California, focuses on office-based procedures that aim to simplify treatment, reduce hospital visits, and offer cost-efficient care for kidney stone patients.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies, specifically targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in the biotechnology sector. By providing antibody-based drugs that enhance immune system functionality, along with technical consultation and drug quality inspection services, Kanova enables its clients to improve drug quality and efficiently advance the field of biomedicine.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

Unified Information Devices Inc., established in 2014 and headquartered in Lake Villa, Illinois, specializes in the development and manufacturing of laboratory animal identification solutions. The company's product portfolio includes implantable transponders, microchips, external transponders, readers, multiple tag programmers, and customized software. These products facilitate efficient tracking and data collection for animals, vials, and cages within research settings, enhancing accuracy and consistency in scientific studies.

CoNextions Medical, Inc. is a medical technology company based in Salt Lake City, Utah, founded in 2011. The company specializes in manufacturing surgical healthcare equipment focused on tendon repair. Its flagship product, CoNextionsTR, is an innovative implant made of stainless steel and ultra-high molecular weight polyethylene, specifically designed to address tendon injuries. This product serves as an alternative to traditional suture repair techniques, allowing for the approximation of tendons that are 1-4mm in thickness and 3-7mm in width. CoNextions Medical aims to enhance patient outcomes by providing a solution that promotes safe, strong, and durable tendon repairs while reducing complications and long-term costs associated with tendon surgeries.

POC Medical Systems is a developer of innovative diagnostic tools focused on breast cancer treatment. The company has created a microfluidic platform that facilitates rapid, point-of-care serum screening. This advanced technology employs antibodies to detect specific bio-markers, utilizing a compact microfluidics system equipped with an integrated reading mechanism. By enabling testing to be performed near or at the site of patient care, POC Medical Systems aims to provide healthcare providers with timely and actionable results that can significantly influence patient treatment decisions.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

Nano-Micro Technology manufactures monodisperse particles in a range of sizes and serves a variety of industries and applications. They provide solutions such as configurable resin development and purification process development. The company's contact modes are phone and physical address.

InSeal Medical Ltd. is a company based in Caesarea, Israel, specializing in the development and manufacturing of percutaneous vascular closure devices. The company's flagship product, the InSeal intravascular closure device, is designed to effectively seal puncture sites after procedures that utilize large bore sheaths, accommodating punctures ranging from 14-21Fr in size and vessels with diameters of 6-10mm. The innovative technology features an internal biodegradable membrane that seals the puncture against the vessel wall, supported by a specially designed self-expandable frame. InSeal Medical Ltd. operates as a subsidiary of E-Pacing Inc., focusing on enhancing patient outcomes through advanced medical device solutions.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

HydroCision develops, manufactures, and markets fluid jet based surgical tools for minimally invasive spine surgery. Its products include the SpineJet HydroSurgery System for tissue ablation and removal, SpineJet HydroDiscectomy Systems for minimally invasive discectomy procedures, and AlloJet systems for bone allograft preparation. The company serves hospitals and physicians through sales representatives.

Claros Diagnostics Inc., established in 2015, specializes in developing portable immunoassay systems designed for point-of-care blood testing. Their innovative product comprises a handheld analyzer and disposable cassettes capable of detecting multiple biomarkers simultaneously. This technology enables healthcare professionals and patients to conduct tests for infectious diseases, cancer, and immune disorders outside traditional laboratory settings.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

Verax Biomedical, Incorporated is a medical products company headquartered in Marlborough, Massachusetts, established in 1999. The company specializes in developing rapid tests for detecting bacterial contaminants in blood cells and tissues intended for transplantation and cellular therapies. Recognizing the unique challenges posed by bacterial contamination—especially since bacteria can multiply in storage conditions, leading to significant risks during transfusions and transplants—Verax Biomedical has created innovative solutions to address this critical health concern. Its product line includes platelet and red cell pan genera detection tests that identify common antigens present on both gram-positive and gram-negative bacteria. By enabling blood banks to detect bacterial contamination effectively, Verax Biomedical plays an essential role in enhancing the safety of blood transfusions and transplants.

Cardiosolutions, Inc. is a medical device company based in West Bridgewater, Massachusetts, founded in 2005. The company specializes in designing and developing innovative solutions for mitral regurgitation, a condition affecting the heart's mitral valve. Its flagship product, Mitra-Spacer, is a reversible implantable device that creates a sealing surface for the mitral valve leaflets, effectively reducing or eliminating regurgitation. This technology offers a less invasive alternative to traditional open-heart surgery, catering to patients of various ages, including those with moderate to severe mitral regurgitation and congestive heart failure. By focusing on minimally invasive procedures, Cardiosolutions aims to enhance patient recovery times and reduce the overall costs associated with heart valve treatment.

Verax Biomedical, Incorporated is a medical products company headquartered in Marlborough, Massachusetts, established in 1999. The company specializes in developing rapid tests for detecting bacterial contaminants in blood cells and tissues intended for transplantation and cellular therapies. Recognizing the unique challenges posed by bacterial contamination—especially since bacteria can multiply in storage conditions, leading to significant risks during transfusions and transplants—Verax Biomedical has created innovative solutions to address this critical health concern. Its product line includes platelet and red cell pan genera detection tests that identify common antigens present on both gram-positive and gram-negative bacteria. By enabling blood banks to detect bacterial contamination effectively, Verax Biomedical plays an essential role in enhancing the safety of blood transfusions and transplants.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease  Discovery and Dexterity Steerable Introducer.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Claros Diagnostics Inc., established in 2015, specializes in developing portable immunoassay systems designed for point-of-care blood testing. Their innovative product comprises a handheld analyzer and disposable cassettes capable of detecting multiple biomarkers simultaneously. This technology enables healthcare professionals and patients to conduct tests for infectious diseases, cancer, and immune disorders outside traditional laboratory settings.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Verax Biomedical, Incorporated is a medical products company headquartered in Marlborough, Massachusetts, established in 1999. The company specializes in developing rapid tests for detecting bacterial contaminants in blood cells and tissues intended for transplantation and cellular therapies. Recognizing the unique challenges posed by bacterial contamination—especially since bacteria can multiply in storage conditions, leading to significant risks during transfusions and transplants—Verax Biomedical has created innovative solutions to address this critical health concern. Its product line includes platelet and red cell pan genera detection tests that identify common antigens present on both gram-positive and gram-negative bacteria. By enabling blood banks to detect bacterial contamination effectively, Verax Biomedical plays an essential role in enhancing the safety of blood transfusions and transplants.

Cylene Pharmaceuticals, Inc. is a biotech pharmaceutical company based in San Diego, California, focused on the discovery and development of small molecule drugs targeting cancer cells. The company specializes in nucleolus targeting agents, which are designed to provide targeted therapeutic solutions for carcinoid and neuroendocrine tumors as well as pediatric brain tumors. Additionally, Cylene develops serine/threonine protein kinase inhibitors and pre-clinical stage oral drug candidates. Established in 1997 as Cyternex, Inc., the company rebranded to Cylene Pharmaceuticals in October 2003. Its innovative approach aims to activate p53 through non-genotoxic pathways, offering improved treatment options for various cancer indications.

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for viral infections and liver diseases. Its research targets include respiratory syncytial virus, hepatitis B virus, hepatitis C virus and nonalcoholic steatohepatitis, as well as other viral pathogens such as SARS-CoV-2 and human metapneumovirus. The company develops HCV therapies, including protease inhibitors such as glecaprevir, and collaborates with AbbVie to identify, develop, and commercialize NS3 and NS3/4A protease inhibitor compounds. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for viral infections and liver diseases. Its research targets include respiratory syncytial virus, hepatitis B virus, hepatitis C virus and nonalcoholic steatohepatitis, as well as other viral pathogens such as SARS-CoV-2 and human metapneumovirus. The company develops HCV therapies, including protease inhibitors such as glecaprevir, and collaborates with AbbVie to identify, develop, and commercialize NS3 and NS3/4A protease inhibitor compounds. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.

Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical, Incorporated is a medical products company headquartered in Marlborough, Massachusetts, established in 1999. The company specializes in developing rapid tests for detecting bacterial contaminants in blood cells and tissues intended for transplantation and cellular therapies. Recognizing the unique challenges posed by bacterial contamination—especially since bacteria can multiply in storage conditions, leading to significant risks during transfusions and transplants—Verax Biomedical has created innovative solutions to address this critical health concern. Its product line includes platelet and red cell pan genera detection tests that identify common antigens present on both gram-positive and gram-negative bacteria. By enabling blood banks to detect bacterial contamination effectively, Verax Biomedical plays an essential role in enhancing the safety of blood transfusions and transplants.

Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.

Pintex Pharmaceuticals, Inc. is a private pharmaceutical company based in Watertown, Massachusetts, specializing in the discovery and development of structure-based cancer therapeutics. Founded in May 1999 by Dr. Kun Ping Lu, Dr. Walter Gilbert, and Dr. Janusz Sowadski, the company focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a critical role in cancer progression. The foundation of Pintex's research and development is rooted in the extensive work conducted at the Salk Institute for Biological Studies and Harvard University, where significant patents and discoveries related to cancer treatment technologies were established. Through its innovative approach, Pintex aims to advance therapeutic options for cancer patients.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Verax Biomedical, Incorporated is a medical products company headquartered in Marlborough, Massachusetts, established in 1999. The company specializes in developing rapid tests for detecting bacterial contaminants in blood cells and tissues intended for transplantation and cellular therapies. Recognizing the unique challenges posed by bacterial contamination—especially since bacteria can multiply in storage conditions, leading to significant risks during transfusions and transplants—Verax Biomedical has created innovative solutions to address this critical health concern. Its product line includes platelet and red cell pan genera detection tests that identify common antigens present on both gram-positive and gram-negative bacteria. By enabling blood banks to detect bacterial contamination effectively, Verax Biomedical plays an essential role in enhancing the safety of blood transfusions and transplants.

Pintex Pharmaceuticals, Inc. is a private pharmaceutical company based in Watertown, Massachusetts, specializing in the discovery and development of structure-based cancer therapeutics. Founded in May 1999 by Dr. Kun Ping Lu, Dr. Walter Gilbert, and Dr. Janusz Sowadski, the company focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a critical role in cancer progression. The foundation of Pintex's research and development is rooted in the extensive work conducted at the Salk Institute for Biological Studies and Harvard University, where significant patents and discoveries related to cancer treatment technologies were established. Through its innovative approach, Pintex aims to advance therapeutic options for cancer patients.

Phase Forward is a prominent provider of integrated data management solutions specifically designed for clinical trials and drug safety. Founded in 1997 by Paul Bleicher, M.D., Ph.D., the company aimed to transition life sciences organizations from traditional paper-based methods to innovative, Internet-enabled solutions. Its flagship product, InForm, has significantly advanced electronic data capture, transforming how clinical data is collected, analyzed, and managed. Phase Forward's technology and global services facilitate the automation and integration of the clinical development process, encompassing study initiation, FDA submission, and post-marketing studies. The company's acquisition of Lincoln Technologies enhanced its capabilities, allowing it to offer comprehensive solutions for tracking and monitoring product efficacy and safety, ultimately leading to more efficient and cost-effective trial management. Prior to its acquisition by Oracle in 2010, Phase Forward was headquartered in Waltham, Massachusetts, with additional offices in the UK, Japan, France, and Australia.